Taysha Gene Therapies, Inc. (TSHA)

NMS – Real Time Price. Currency in USD

6.34

+0.13 (2.09%)

At close: Jun 26, 2026, 4:00 PM EDT

6.26

-0.08 (-1.22%)

After-hours: Jun 26, 2026, 7:59 PM EDT

05.06.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company's common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

01.06.2026

Taysha Gene Therapies: Shortened Timeline Increases The Potential

Taysha Gene Therapies is now a one-drug company, fully reliant on TSHA-102 for Rett syndrome after discontinuing its previous pipeline. I rate TSHA as a Buy, citing strong cash reserves, promising early TSHA-102 data, and an accelerated FDA pathway skipping Phase 3. TSHA-102's miRARE technology offers a safety edge over competitor NGN-401, with pivotal data expected in late 2026 and potential commercialization by 2027/2028.

06.05.2026

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

06.05.2026

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.

01.05.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, restricted stock units (RSUs) representing 188,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

29.04.2026

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time.

27.04.2026

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration

Videos

No Data

There is no data to display

Press releases

05.06.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06.05.2026

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

01.05.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03.04.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies, Inc. (TSHA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies: Shortened Timeline Increases The Potential

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Videos

No Data

Press releases

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies: Shortened Timeline Increases The Potential

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Videos

No Data

Press releases

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Taysha Gene Therapies, Inc. (TSHA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies: Shortened Timeline Increases The Potential

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Videos

No Data

Press releases

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies: Shortened Timeline Increases The Potential

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Videos

No Data

Press releases

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)